ADIM
NVCR icon

Alpha DNA Investment Management’s NovoCure NVCR Stock Holding History

Alpha DNA Investment Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-24,950
Closed -$390K – 239
2024
Q3 		$390K Buy
24,950
+4,597
+23% +$83.4K 0.15% 184
2024
Q2 		$349K Buy
+20,353
New +$358K 0.14% 182
2021
Q2 		– Sell
-28
Closed -$3K – 459
2021
Q1 		$3K Sell
28
-6
-18% -$949 ﹤0.01% 493
2020
Q4 		$5K Buy
+34
New +$4.65K 0.01% 370

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Alpha DNA Investment Management's NVCR Position: Q4 2024 in Review

Alpha DNA Investment Management sold out of NovoCure (NVCR) in Q4 2024, closing a stake of 24,950 shares — an estimated $390K sold.

Alpha DNA Investment Management first reported a position in NVCR in Q4 2020 and held it in 4 quarters. The position peaked at $390K in Q3 2024. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2024.

  • Alpha DNA Investment Management reported no remaining NovoCure position as of Q4 2024 after selling out during the quarter.
  • Alpha DNA Investment Management sold 24,950 NovoCure shares in Q4 2024, an estimated $390K.
  • Alpha DNA Investment Management first reported a position in NovoCure in Q4 2020 and held it in 4 quarters.
  • Alpha DNA Investment Management's NovoCure position peaked at $390K in Q3 2024.
  • 238 funds tracked by Wall St. Rank held NovoCure as of Q4 2024.

Based on Alpha DNA Investment Management's 13F filing for Q4 2024, filed 13 Feb 2025.